Cutera announces a new U.S. Food and Drug Administration Clearance of AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. This is the first acne therapy to claim long term effectiveness for mild, moderate and severe acne.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CUTR:
- SetPoint Medical names Cutera CFO Rohan Seth as new CFO
- Is CUTR a Buy, Before Earnings?
- Short Report: Bears boost Vivid Seats position to record high as stock bottoms
- Jefferies med supplies/devices analyst holds analyst/industry conference call
- Plants, Mowry say Cutera special committee made ‘misleading’ statements